Company Overview of Valbiotis SA
Valbiotis SA develops nutrition solutions to prevent cardiometabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. Its products in Phase I/II clinical trials include VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product, which provides nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. The company’s health supplement products under clinical development Phase comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VA...
40 rue Chef de Baie
La Rochelle, 17000
Founded in 2014
Key Executives for Valbiotis SA
Valbiotis SA does not have any Key Executives recorded.
Valbiotis SA Key Developments
Valbiotis SA Appoints Pascal SIRVENT as Director of Discovery and Preclinical Research
Sep 14 17
Valbiotis SA announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017. Pascal SIRVENT has been contributing to company's growth for several years as a member of the Scientific Committee and head of collaborative projects between the University of Clermont Auvergne and VALBIOTIS. Co-inventor of several technologies crucial to the development of VALBIOTIS, Pascal has extensive preclinical research expertise. He has published some 30 articles in international scientific journals and given numerous presentations at congresses. With over 10 years experience in research, Pascal SIRVENT will be bringing his in-depth expertise in metabolic diseases and nutrition.
VALBIOTIS Opens New Clinical Investigation Center at the Institut Pasteur in Lille
Sep 6 17
VALBIOTIS announced the opening of a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on Totum-63. Following the conclusive results obtained for the Phase I/II study, VALBIOTIS has initiated a Phase IIa study to demonstrate the efficacy of a high dose of the active ingredient of Valedia® on prediabetics (ultimate proof of efficacy). Like the three other trials carried out as part of the Phase II study, this Phase IIa is expected to be completed by 2019 in view of the submission of a proprietary health claim request, first, to the EFSA. This will make it possible to market the product in Europe by 2020, and then in the United States by 2021 after a health claim request has been submitted to the FDA, once EFSA approval has been obtained. The opening of this new Clinical Investigation Center at the Institut Pasteur in Lille which follows the opening of the first Biofortis Mérieux NutriSciences Clinical Investigation Center in Nantes in November 2016 will help accelerate the recruitment of volunteers for the Phase IIa clinical study. Professor Jean-Michel Lecerf is the investigator for the clinical study that will be conducted at this Clinical Investigation Center.
Valbiotis SAS Presents at BioMed Event by Invest Securities, Jan-26-2017
Jan 5 17
Valbiotis SAS Presents at BioMed Event by Invest Securities, Jan-26-2017 . Venue: Salons Hoche, 9 avenue Hoche, 75008 Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries